Follow this preprint
Favipiravir In Adults with Moderate to Severe COVID-19: A Phase 3 Multicentre, Randomized, Double-Blinded, Placebo-Controlled Trial
View ORCID ProfileSrinivas Shenoy, View ORCID ProfileSagar Munjal, View ORCID ProfileSarah Al Youha, View ORCID ProfileMohammad Alghounaim, View ORCID ProfileSulaiman Almazeedi, View ORCID ProfileYousef Alshamali, View ORCID ProfileRichard H Kaszynski, View ORCID ProfileSalman Al-Sabah, Kuwait Clinical Trial Group
doi: https://doi.org/10.1101/2021.11.08.21265884
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Srinivas Shenoy
1Dr Reddy’s Laboratories Limited, 8-2-337, Road No.3, Banjara Hills, Hyderabad-500 034, India; Email:
Sagar Munjal
2Dr Reddy’s Laboratories Limited, 8-2-337, Road No.3, Banjara Hills, Hyderabad-500 034, India; Email:
Sarah Al Youha
3Jaber Al-Ahmad Al-Sabah Hospital, Kuwait, Khalid Ben AbdulAziz Street, South Surra-47781, Kuwait; Email:
Mohammad Alghounaim
4Jaber Al Ahmad Hospital at Mishref Field Hospital, Mubarak Al-Abdullah Street, Mishref-90005, Kuwait; Email:
Sulaiman Almazeedi
5Jaber Al Ahmad Hospital at Mishref Field Hospital, Mubarak Al-Abdullah Street, Mishref-90005, Kuwait; Email:
Yousef Alshamali
6Jaber Al Ahmad Hospital at Mishref Field Hospital, Mubarak Al-Abdullah Street, Mishref-90005, Kuwait; Email:
Richard H Kaszynski
7Emergency and Critical Care Center, Tokyo Metropolitan Hiroo Hospital, 2-34-10, Ebisu, Shibuya-ku, Tokyo 150-0013, Japan; Email:
Salman Al-Sabah
8Jaber Al Ahmad Hospital at Mishref Field Hospital, Mubarak Al-Abdullah Street, Mishref-90005, Kuwait; Email:

Data Availability
All data produced in the present study are available upon reasonable request to the authors
Posted November 09, 2021.
Favipiravir In Adults with Moderate to Severe COVID-19: A Phase 3 Multicentre, Randomized, Double-Blinded, Placebo-Controlled Trial
Srinivas Shenoy, Sagar Munjal, Sarah Al Youha, Mohammad Alghounaim, Sulaiman Almazeedi, Yousef Alshamali, Richard H Kaszynski, Salman Al-Sabah, Kuwait Clinical Trial Group
medRxiv 2021.11.08.21265884; doi: https://doi.org/10.1101/2021.11.08.21265884
This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
2
Community Reviews
0
Automated Services
0
Blogs/Media
0
Author Videos
Subject Areas
- Addiction Medicine (418)
- Allergy and Immunology (740)
- Anesthesia (217)
- Cardiovascular Medicine (3171)
- Dermatology (268)
- Emergency Medicine (469)
- Epidemiology (13143)
- Forensic Medicine (17)
- Gastroenterology (878)
- Genetic and Genomic Medicine (4971)
- Geriatric Medicine (458)
- Health Economics (761)
- Health Informatics (3130)
- Health Policy (1114)
- Hematology (418)
- HIV/AIDS (987)
- Medical Education (462)
- Medical Ethics (121)
- Nephrology (511)
- Neurology (4720)
- Nursing (250)
- Nutrition (699)
- Oncology (2432)
- Ophthalmology (691)
- Orthopedics (272)
- Otolaryngology (335)
- Pain Medicine (315)
- Palliative Medicine (88)
- Pathology (523)
- Pediatrics (1263)
- Primary Care Research (536)
- Public and Global Health (7289)
- Radiology and Imaging (1631)
- Respiratory Medicine (953)
- Rheumatology (468)
- Sports Medicine (409)
- Surgery (527)
- Toxicology (66)
- Transplantation (225)
- Urology (196)